» Articles » PMID: 1717147

Folate-binding Protein is a Marker for Ovarian Cancer

Overview
Journal Cancer Res
Specialty Oncology
Date 1991 Oct 1
PMID 1717147
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

We describe the isolation of a complementary DNA (cDNA) sequence encoding the ovarian cancer-associated antigen recognized by monoclonal antibody MOv18 and its identification as a high-affinity folate-binding protein (FBP). Functional cDNA clones were isolated using mRNA from the ovarian carcinoma cell line SKOV3 and colon carcinoma cell line HT29, by transient expression in WOP cells and selection of expressing cells by adhesion to antibody-coated magnetic beads. The cDNAs differed in the lengths of 5'- and 3'-noncoding regions, but they encoded identical peptides. A database search clearly showed them to be adult high-affinity FBPs with amino acid sequences identical with those isolated from normal placenta and several carcinoma cell lines. Reactivity of cell lines with MOv18 was quantitatively consistent with the expression of FBP mRNA. Southern hybridizations show evidence of a family of related genes and/or pseudogenes and were mapped to chromosome 11q13.3-14.1 by fluorescent in situ hybridization using cosmid clones containing part of this region. Also identified were two PstI polymorphisms of four and three alleles, respectively, and a two-allele MspI polymorphism. The folate-binding protein locus was not amplified in any of the 16 carcinoma cell lines tested and in only 1 of 10 serous adenocarcinomas, indicating that overexpression of FBP in ovarian cancer cannot, in general, be due to gene amplification.

Citing Articles

Enhanced anti-tumor activity of transferrin/folate dual-targeting magnetic nanoparticles using chemo-thermo therapy on retinoblastoma cancer cells Y79.

Sadri E, Khoee S, Moayeri S, Ali B, Pirhajati Mahabadi V, Shirvalilou S Sci Rep. 2023; 13(1):22358.

PMID: 38102193 PMC: 10724238. DOI: 10.1038/s41598-023-49171-5.


Novel Development of Nanoparticles-A Promising Direction for Precise Tumor Management.

Zhang D, Tang Q, Chen J, Wei Y, Chen J Pharmaceutics. 2023; 15(1).

PMID: 36678653 PMC: 9862928. DOI: 10.3390/pharmaceutics15010024.


Induction of ADCC by a folic acid-mAb conjugate prepared by tryptophan-selective reaction toward folate-receptor-positive cancer cells.

Tagawa H, Maruyama K, Sasaki K, Konoue N, Kishimura A, Kanai M RSC Adv. 2022; 10(28):16727-16731.

PMID: 35498849 PMC: 9053046. DOI: 10.1039/d0ra03291c.


Bifunctional folic-conjugated aspartic-modified FeO nanocarriers for efficient targeted anticancer drug delivery.

Khalil M, Haq E, Dwiranti A, Prasedya E, Kitamoto Y RSC Adv. 2022; 12(8):4961-4971.

PMID: 35425526 PMC: 8981417. DOI: 10.1039/d1ra08776b.


Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer.

Wallace-Povirk A, Hou Z, Nayeen M, Gangjee A, Matherly L Cancers (Basel). 2022; 14(1).

PMID: 35008360 PMC: 8750473. DOI: 10.3390/cancers14010191.